A resolution expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Sponsor

Full profile: /officials/S001184
Source: Congress.gov · FEC
Cosponsors (8)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
- Alex Padilla (D-CA)Original· 2026-09-30
- Cindy Hyde-Smith (R-MS)Original· 2026-09-30
- Cory A. Booker (D-NJ)Original· 2026-09-30
- Elizabeth Warren (D-MA)Original· 2026-09-30
- James Lankford (R-OK)Original· 2026-09-30
- Katie Boyd Britt (R-AL)Original· 2026-09-30
- Tina Smith (D-MN)Original· 2026-09-30
- Todd Young (R-IN)Original· 2026-09-30
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S5299; text: CR S5270)
2026-09-30
Source: Congress.gov
Plain-English Summary
Plain-English summary pending. Introduced on 2026-09-30. Check back soon — summaries are generated as bills progress through Congress.
Subjects
Full Bill Text
Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.
[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. Res. 940 Agreed to Senate (ATS)] <DOC> 119th CONGRESS 2d Session S. RES. 940 Expressing support for the designation of September 2026 as ``Sickle Cell Disease Awareness Month'' in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES September 30, 2026 Mr. Scott of South Carolina (for himself, Mr. Booker, Mr. Young, Ms. Smith, Mrs. Britt, Mr. Padilla, Mrs. Hyde-Smith, Ms. Warren, and Mr. Lankford) submitted the following resolution; which was considered and agreed to _______________________________________________________________________ RESOLUTION Expressing support for the designation of September 2026 as ``Sickle Cell Disease Awareness Month'' in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease. Whereas sickle cell disease (referred to in this preamble as ``SCD'') is an inherited blood disorder that is a major health problem in the United States and worldwide; Whereas SCD can result in multiple medical complications, including anemia, jaundice, gallstones, strokes, restricted blood flow, damaged tissue in the liver, spleen, and kidneys, and death; Whereas SCD causes acute and chronic episodes of severe pain; Whereas SCD affects an estimated 100,000 individuals in the United States; Whereas approximately 1,800 to 2,000 babies are born with SCD each year in the United States, with the disease occurring in approximately 1 in 365 newborn Black or African American infants and 1 in 16,300 newborn Hispanic-American infants, and can be found in individuals of Mediterranean, Middle Eastern, Asian, and Indian origin; Whereas more than 2,000,000 individuals in the United States have the sickle cell trait and 1 in 13 Black or African Americans carries the trait; Whereas there is a 1 in 4 chance that a child born to parents who both have the sickle cell trait will have the disease; Whereas the life expectancy of an individual with SCD in the United States is often severely limited, with some estimates showing a shortened life expectancy of more than 20 years; Whereas sickle cell anemia is a common cause of childhood stroke, and in 2019, fewer than half of children with sickle cell anemia who were 2 to 16 years old received the recommended screening for stroke; Whereas, in 2019, only 2 in 5 children with sickle cell anemia who were 2 to 9 years old used recommended medication that can prevent sickle cell anemia complications; Whereas, in 2020, the National Academies of Science, Engineering, and Medicine developed a comprehensive strategic plan and blueprint for action to address sickle cell disease, which, among other things, cited the need for new innovative therapies and promoting widespread patient access to approved treatments; Whereas, in 2023, hematopoietic stem cell transplantation (commonly known as ``HSCT'') was the only cure for SCD, and the Food and Drug Administration has since approved 2 gene therapies that have been demonstrated to cure SCD; Whereas, in 2023, the Food and Drug Administration approved Casgevy and Lyfgenia, the first 2 cell-based gene therapies to treat certain patients with SCD; Whereas, on July 1, 2026, the Food and Drug Administration expanded the approval of Casgevy to include certain patients aged 2 years and older with SCD and recurrent vaso-occlusive crises or transfusion-dependent b thalassemia; Whereas more research is needed to…
Show the remaining 196 wordsHide the remaining 196 words
find more treatments and cures to help individuals with SCD; Whereas the Centers for Medicare & Medicaid Services is operating the cell and gene therapy access model to support outcomes-based agreements between participating Medicaid programs and manufacturers of gene therapies for SCD: Whereas 32 States, the District of Columbia, and Puerto Rico, representing approximately 84 percent of Medicaid beneficiaries living with SCD, are participating in the cell and gene therapy access model; and Whereas September 2026 has been designated as ``Sickle Cell Disease Awareness Month'' in order to educate communities across the United States about SCD, including early detection methods, effective treatments, and preventative care programs with respect to complications from SCD and conditions related to SCD: Now, therefore, be it Resolved, That the Senate-- (1) supports the goals and ideals of Sickle Cell Disease Awareness Month; and (2) encourages the people of the United States to hold appropriate programs, events, and activities during Sickle Cell Disease Awareness Month to raise public awareness of the sickle cell trait, preventative care programs, treatments, and other patient services for those suffering from sickle cell disease, complications from sickle cell disease, and conditions related to sickle cell disease. <all>
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- SRES947A resolution designating September 2026 as "National Childhood Cancer Awareness Month".Introduced · 2026-09-30
- S5641Opportunities for Nuclear Energy Investment ActReferred to Committee · 2026-09-30
- S5527Birth Tourism Elimination ActReferred to Committee · 2026-09-24
- S5551Critical Mineral Executive Coordination Act of 2026Referred to Committee · 2026-09-24